Table 2.

Estimated patients and market shares broken down by year and therapy: base case and sensitivity analysis 1*†.

	Year 1	Year 2	Year 3
Reference Scenario
Anakinra	0 (0.0%)	0 (0.0%)	0 (0.0%)
Canakinumab	76 (100.0%)	79 (100.0%)	82 (100.0%)
Total	76 (100.0%)	79 (100.0%)	82 (100.0%)
Alternative Scenario
Anakinra	30 (39.5%)	40 (50.6%)	49 (59.8%)
Canakinumab	46 (60.5%)	39 (49.4%)	33 (40.2%)
Total	76 (100.0%)	79 (100.0%)	82 (100.0%)

*Number of patients rounded at the first integer. †Percentages rounded to the first decimal number.